Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival

Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): What to add and what to leave out

(2019) C. Proto et al.   CANCER TREATMENT REVIEWS

TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer

(2019) Jitka Fucikova et al.   CLINICAL CANCER RESEARCH

Future Research Goals in Immunotherapy

(2019) Tyler W. Hulett et al.   Surgical Oncology Clinics of North America

The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy

(2019) Anne Geller et al.   Frontiers in Immunology

TIM-3 Regulates CD103 + Dendritic Cell Function and Response to Chemotherapy in Breast Cancer

(2018) Álvaro de Mingo Pulido et al.   CANCER CELL

The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer

(2018) Xiaoling Xu et al.   INTERNATIONAL JOURNAL OF CANCER

Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients

(2018) Lívia Rojkó et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Is there a role for immunotherapy in malignant pleural mesothelioma?

(2018) Alfredo Tartarone et al.   MEDICAL ONCOLOGY

Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer

(2018) Junghoon Shin et al.   Cancer Research and Treatment

Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer

(2018) Emelie Rådestad et al.   OncoImmunology

Tim-3 and its role in regulating anti-tumor immunity

(2017) Madhumita Das et al.   IMMUNOLOGICAL REVIEWS

LAG3 (CD223) as a cancer immunotherapy target

(2017) Lawrence P. Andrews et al.   IMMUNOLOGICAL REVIEWS

Breast cancer: LAG3 expression indicates favourable outcomes

(2017) Peter Sidaway   Nature Reviews Clinical Oncology

GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses

(2017) Zefang Tang et al.   NUCLEIC ACIDS RESEARCH

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

(2017) Enfu Hui et al.   SCIENCE

Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

(2017) Alice O. Kamphorst et al.   SCIENCE

Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells

(2017) Haifa Shen et al.   SEMINARS IN IMMUNOLOGY

PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer

(2016) John R. Webb et al.   GYNECOLOGIC ONCOLOGY

TIM-3 Regulates Distinct Functions in Macrophages

(2016) Ranferi Ocaña-Guzman et al.   Frontiers in Immunology

Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma

(2015) Liyun Xu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

(2015) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

T Cell Ig Mucin-3 Promotes Homeostasis of Sepsis by Negatively Regulating the TLR Response

(2013) X. Yang et al.   JOURNAL OF IMMUNOLOGY

TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression

(2012) Xin Gao et al.   PLoS One

PrognoScan: a new database for meta-analysis of the prognostic value of genes

(2009) Hideaki Mizuno et al.   BMC Medical Genomics